Ｐａｇｅ 4037 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼Pharming Announces cleskWepetiep 08/7/24(木) 6:02 ─────────────────────────────────────── ■題名 ： Pharming Announces ■名前 ： cleskWepetiep <setjrtj@googlemail.com> ■日付 ： 08/7/24(木) 6:02 ■Ｗｅｂ ： http://yandex.com -------------------------------------------------------------------------
| LEIDEN, The Netherlands, July 11, 2008- Biotech business Pharming band NV (撤harming or 鍍he companionship) (NYSE Euronext: PHARM) announced today bullish results from non-stop make known-hallmark studies with recombinant kindly C1 inhibitor (Rhucinｮ) for the treatment of wise attacks of inherited Angioedema (HAE). The unquestioned results are from the treatment of 123 wise HAE attacks in 64 patients with distinct doses of Rhucinｮ in the persistent European and North American expand-name studies. Rhucinｮ has been acheter cialis sheltered and things in patients receiving up to nine treatments with no suggestion of decreasdd answer to the over drug. Importantly, all seven achat cialis laryngeal attacks treated in these studies responded in a jiffy to Rhucinｮ. The expand-characterize matter are uncnanging with findings from Pharming痴 two randomized, ambiguous-shutters, placebo-lead led studies of Rhucinｮ with a median nonetheless to origin of achat cialis of one hour and a median nonetheless to slightest symptoms of four hours. Dr. Bruno Giannetti, Chief Operations public official at Pharming, commented: 展e are exceptionally contented with these confident results with Rhucinｮ. They ensure the clinical benefits of Rhucvinｮ, also in duplicate treatment, without showing any adverse reactions or protected answers. Furthermore, the compute individual of treatments has actually acheter cialisd , including the eminent treatment of sedate potentially soul-minatory lafyngeal attacks. We precise much achat cialis the fortifying of the investigators and patients with HAE with these clinical trials. These studies are an outstanding contribution to making Rhucinｮ close by for HAE patients worldwide. The results from pliant-characterize studies ensure Rhucinｮ to be sheltered and outstanding in the duplicate treatment of discerning HAE attacks at divers dosage regimens. No clinically fitting adverse reactions were reported from these studies. The expand-characterize treatments report a sub stantial multiply to the Rhucinｮ clinical informationbase and command be employed to certify planned regulatory submissions. around Rhucinｮ and HAE Rhucinｮ (recombinant kindlyy C1 esterase inhibitor) is a benefactor protein developed result of Pharming痴 proprietary technology where the compassionate protein is expressed in bleed of transgenic rabbits. Rhucinｮ is currently call of maturity for treatment of patients with wise attacks of inheritable Angioedema (HAE). HAE is a compassionate genetic pharming announces cainured to by a shortfall of C1 inhibitor job and results in an overreaction of the protected system. The affliction is characterized by discerning attacks of nociceptive and in some cases dreadful protrusion of a variety of pconcludingic tissues (edema), which may end up to five days when untreated. around Pharming band NVPharming band NV is developing innovative products for the treamtent of genetic shambless, ageing blights, specialty products for surgical indications, intermediates for diversified applications and nutritional products. Pharming has two products in behindhand rostrum show business maturity - Rhucinｮ for inheritable Angioedema and benefactor lactoferrin for use in rations products. The advanced technologies of the business incorporate innovative platforms for thue effort of protein therapeutics, technology and processes for the purification and formulation of these products, as reasonably as technology in the speciality of DNA state (via DNage). |